Sunday, 21 June 2026

Vol. 1 · No. 19 Sunday, 21 June 2026 “The record, not the rumour.”

FDA & Regulatory

FDA Advisory Panel Backs Moderna's mRNA Flu Vaccine 9-0, Setting August 5 Decision Deadline

VRBPAC voted unanimously that mFLUSIVA's benefits outweigh its risks in adults 50 and older — but FDA has not yet approved the shot, and a two-track pathway for different age groups adds complexity.

Marcus Webb, FDA & Regulatory Desk · 3 min read

The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 9-0 on June 18, 2026, that the benefits of Moderna’s mFLUSIVA (mRNA-1010) outweigh its risks for adults aged 50 and older — clearing the final advisory hurdle before the agency’s August 5 PDUFA decision. The unanimous vote is significant, but it is a recommendation, not an approval.

A Split Approval Pathway

Continue reading →

Also leading today

Opinion

A Unanimous Vote Is Not an Approval: Reading the mFLUSIVA Panel Decision Clearly

The 9-0 VRBPAC result is meaningful — but the numbers behind it, the bifurcated approval tracks, and an August deadline tell a more complicated story than the headline suggests.

The Vital Record · Editorial · 2 min

Devices & Safety

FDA Issues Class I Recall for Boston Scientific ACCOLADE Pacemakers After 4 Deaths, 2,557 Injuries

A battery manufacturing defect can permanently lock affected devices into a limited-function Safety Mode; the Brady SMR6 software update applied by a clinician prevents future Safety Mode entry but cannot reverse it — devices already in Safety Mode require clinical assessment and may need replacement.

Dr. Nadia Haq, Devices & Diagnostics Desk · 3 min

In brief

Public Health Measles Cases Top 2,100 Across 41 Jurisdictions, Putting U.S. Elimination Status at Risk A second straight year above 2,000 confirmed cases has forced a delay in the PAHO review that could strip the U.S. of its 26-year elimination designation.
Clinical Trials Once-Weekly HIV Pill Meets Non-Inferiority Targets in Twin Phase 3 Trials Preliminary Week 48 results from ISLEND-1 and ISLEND-2 show the oral islatravir/lenacapavir combination held its own against daily standard-of-care regimens — but full data, safety details, and a regulatory timeline are not yet public.
Research Lab Study: Engineered Immune Progenitor Cells Target Leukemia and Solid Tumors in Mice Preclinical research from USC shows that CAR-equipped granulocyte-monocyte progenitors can suppress cancer in mouse models — but human trials have not begun and the results have not been replicated in humans.
Digital Health & AI An AI Agent Outperformed Physicians on Simulated ED Cases — in a Sandboxed EHR, Not a Real Hospital A peer-reviewed Nature study tested MIRA on 574 retrospective emergency cases across eight diagnoses; the system has no regulatory clearance and has never treated a real patient.
Clinical Trials Cancer-Clot Trial for Abelacimab Terminated Before Reaching Its Primary Endpoint The ASTER Phase 3 study of the Factor XI inhibitor versus apixaban in cancer-associated VTE has been halted, with no results posted and no reason disclosed in the public registry.
FDA & Regulatory FDA Sends Cytisinicline Back to the Factory, Not the Drawing Board Achieve Life Sciences receives a manufacturing CRL for its plant-derived smoking cessation drug — the clinical evidence is intact, but the supply chain needs work before approval can proceed.

← The archive